Patent GB-417715-A (GB)
Title: Improvements in the manufacture and production of pharmaceutical preparations
IPC: A61K9/00
Filed: 1932-12-29
Abstract: Lysocithin for use in treating rheumatism is prepared by the action of bee stings, or the secretion of snakes, on lecithin. Egg yolks are caused to react with bee stings in the presence of a small quantity of a zinc or cadmium salt, as a catalyst, the compound so obtained being treated with cadmium chloride to form an insoluble double salt which is decomposed by alcoholic ammonia to yield free lysocithin.ALSO:Pharmaceutical preparations for subcutaneous or like injection are prepared by incorporating an active substance with an aqueous emulsion of a lipoid containing also an antiseptic, a stabilizer for the emulsion, and a regulator, i.e. a substance accelerating or retarding the rate of release of the active substance from the emulsion within the body of the patient.  It is stated that drugs and the like may be administered in large doses but come into action gradually over a long period.  The lipoids comprise fatty non-drying animal, fish or vegetable oils, synthetic glycerides of long chain fatty acids, phosphatides, and wool fat and its constituents.  Phosphatides such as lecithin and kephalin, and wool fat and its constituents serve both as lipoids and as stabilizers. The stabilizers employed are salts of long chain, saturated or unsaturated, fatty of resinic acids containing at least 10 carbon atoms and which may be hydroxylated.  The basic constituent may be ammonia, a metal such as sodium, potassium, lithium or strontium, or an amine.  Examples of suitable amines and acids are given.  Salts obtained by saponifying a natural resin may be employed.  Regulators accelerating release of the active substance comprise aromatic acids, including sulphonic acids, and their salts, sodium sulphite, terpenes, various classes of alcohols, purine derivatives, and bile acids and their salts; those retarding release comprise cholesterin, cuffeic acid, various tunnic acids and related compounds, and organic or inorganic calcium salts.  Numerous specific examples of regulators are given.  Suitable antiseptics are 2-butoxy-21.61-diamino-5.51-azopyridine, trypan blue, trypaflavine, 7 - iodo - 8 - hydroxyquinoline - 5 - sulphonic acid sodium salt, p-hydroxy-benzoic acid n-propyl ester, and p-hydroxybenzoic acid methyl ester.  The consistency of the remedial preparations may be increased by the addition of various waxes, tallow, and esters of cetyl ceryl or myricyl alcohols with fatty acids containing at least 20 carbon atoms. The emulsions may be made with water, aqueous salt solutions, or aqueous glycerine.  Pharmaceutically active substance to be incorporated in the emulsions may be annesthetis, alkaloids, hormones, or lysocithin.  Lysocithin results from the action of bee stings or the secretion of snakes on lecithin and may be prepared by reacting egg yolks with bee stings in the presence of a small quantity of a zinc or cadmium salt as a catalyst, the compound so obtained being treated with cadmium chloride to form an insoluble double salt which is decomposed by alcoholic ammonia to yield free lysocithin.  Specific examples relate to compositions containing, as active substances, strophanthin, tribromoethyl alcohol, insulin, adrenalin bitartrate, hyoscin, strychnine nitrate, female sexual hormone, and delta-corbamido-ornithin.  Specification 378,198 is referred to. The Provisional Specification states that the use of the regulating and antiseptic ingredients is optional and includes two additional examples of preparations containing as active ingredients morphine hydrochloride, and novocain and lysocithin, respectively.